Skip to content

Dorte X. Gram

Director of the Board and Chief Executive Officer (CEO)

Dorte X. Gram (Danish, born 1969) is the founder and Chief Executive Officer (CEO) of Pila Pharma. She is XENIA PHARMA’s representative in Pila Pharma’s Board of Directors.

Dorte X. Gram is the inventor of the principle of treating diabetes and obesity with TRPV1 antagonists – a discovery-by-surprise during her PhD studies at Novo Nordisk, Denmark. In 2008, she acquired the rights to the invention from Novo Nordisk, Denmark, had use-patents issued via her mother-company XENIA PHARMA, Denmark and, in 2014, founded Pila Pharma in Sweden as a subsidiary.

Besides her innovative and entrepreneurial drive, Dorte X. Gram provides experience to Pila Pharma in diabetes project management and planning including preclinical and clinical pharmacology, toxicology and regulatory affairs. She further has an extensive network in diabetes and runs PILA as a virtual company with a basic focus on target product profile, lean project management and engagement of her various professional contacts and other experts.

Dorte X Gram graduated as veterinarian (DVM) in 1996 and was awarded the PhD title in 2003. She has profound experience from the life-science industry, whereof more than 10 years were in Diabetes Research & Development at Novo Nordisk A/S, Denmark working with various project teams within the diabetes and obesity research areas with small molecules and peptides including insulin- and GLP-1- analogues. She is the author of several scientific publications with a focus on TRPV1 in diabetes or anti-diabetic agents as well as of patents related to TRPV1 in diabetes and to basal insulin analogues.

Dorte X. Gram is an expert in Pharmacology and Toxicology and previously, she has worked as Teaching and Scientific Assistant  at the University of Copenhagen, Denmark (1996-1999), PhD Student, Research Scientist and Clinical Pharmacologist at Novo Nordisk, Denmark (1999-2009), Associate Professor of Pharmacology at the University of Copenhagen, Denmark (2009-2010), External lecturer of Pharmacology & Toxicology, Roskilde University, Denmark (2010-2014), as Senior Toxicologist and Business Area Manager, Dept. of Human Health and Safety, DHI, Denmark (2010-2011), Senior Consultant and CEO of XENIA PHARMA, Denmark (2011-present) and CEO of Pila Pharma, Sweden (2014-present).

Share ownership in the company: 5 195 086 (indirect) corresponding to 21,83% of votes and capital.





Back To Top